> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Voucher Used on Rinvoq Approval
- URL: https://www.fdaweb.com/priority-voucher-used-on-rinvoq-approval/
- Published: 2019-09-09T12:00:00.000Z
- Updated: 2026-09-15T01:48:24.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144952

*Federal Register* notice: FDA has announced that it accepted a priority review voucher to approve AbbVie’s Rinvoq (upadacitnib) on 8/16\. The once-daily oral Janus kinase inhibitor is indicated for treating adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-09-06/pdf/2019-19298.pdf?ref=fdaweb.com).